Outset Medical, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Outset Medical develops and sells the Tablo Hemodialysis System, an FDA-cleared dialysis platform designed for hospital, clinic, and home use. The filing covers the three and six months ended June 30, 2023, compared with the same periods in 2022. The company remains loss-making and is investing in commercial expansion, home dialysis adoption, manufacturing, and product development.
Key Financial Metrics
| Metric | Q2 2023 | Q2 2022 | Six Months 2023 | Six Months 2022 |
|---|---|---|---|---|
| Total revenue | $36.0 million | $25.1 million | $69.5 million | $55.6 million |
| Product revenue | $29.3 million | $19.6 million | $57.1 million | $45.3 million |
| Service and other revenue | $6.7 million | $5.4 million | $12.4 million | $10.3 million |
| Gross profit | $7.7 million | $3.8 million | $14.1 million | $8.2 million |
| Gross margin | 21.4% | 15.1% | 20.3% | 14.8% |
| Loss from operations | $(43.5) million | $(43.7) million | $(87.0) million | $(80.2) million |
| Net loss | $(44.0) million | $(43.8) million | $(88.0) million | $(80.7) million |
| Net loss per share | $(0.90) | $(0.92) | $(1.79) | $(1.69) |
- Q2 revenue increased 44%, driven by 49% growth in product revenue. Six-month revenue increased 25%.
- Console revenue increased $6.5 million in Q2 and $7.3 million year to date; consumables revenue increased $3.2 million and $4.5 million, respectively, reflecting growth in the installed base.
- Operating expenses increased 8% in Q2 and 14% year to date. Six-month expenses included $18.6 million of stock-based compensation, compared with $12.4 million in the prior-year period.
- Interest income increased because of higher interest rates and investment balances, while interest expense increased substantially following the new SLR term loan.
- Cash used in operations was $72.9 million for the six months, compared with $76.9 million in the prior-year period.
- Investing activities provided $29.8 million, primarily from $129.3 million of investment maturities, partly offset by $97.8 million of purchases and $1.6 million of capital expenditures.
Balance Sheet, Debt, and Liquidity
- As of June 30, 2023, cash and cash equivalents were $36.4 million, short-term investments were $186.4 million, and restricted cash was $3.3 million.
- Cash, cash equivalents, and short-term investments totaled $222.8 million; including restricted cash, the total was $226.1 million.
- Total liabilities were $151.3 million, including a $96.6 million carrying value for the $100.0 million SLR term loan.
- The SLR term loan bears interest at one-month term SOFR, subject to a 2.75% floor, plus 5.15%, or 10.29% as of June 30, 2023. Principal is generally due November 1, 2027, with interest-only payments permitted through November 2026, subject to conditions.
- The company also has access to an asset-based revolving facility with an initial commitment of $25.0 million, subject to borrowing-base limitations and other conditions.
- Management expects existing liquidity, sales proceeds, and available debt financing to fund anticipated needs for at least the next 12 months from the filing date, although significant future losses and operating cash requirements are expected.
Material Changes Versus the Prior Comparable Period
- Revenue growth accelerated, particularly in console and consumables sales, as the installed base expanded.
- Gross margin improved by 6.3 percentage points in Q2 and 5.5 percentage points for the first six months, primarily from console cost reductions and, year to date, higher average selling prices.
- Despite stronger revenue and gross profit, the company remained deeply loss-making because operating expenses continued to exceed gross profit.
- Interest expense increased by $2.6 million in Q2 and $5.1 million for the first six months due to the SLR term loan.
- Cash burn from operations improved modestly year over year, but the company’s accumulated deficit increased to $877.0 million.
- Inventory declined to $44.5 million from $51.5 million at year-end 2022, while accounts receivable increased to $36.9 million from $28.1 million.
Guidance, Outlook, Risks, and Unusual Items
- No specific revenue, margin, or earnings guidance is provided in the filing. Management expects significant expenses and operating losses to continue in the near term.
- Management is pursuing gross-margin expansion through in-house console manufacturing, Mexico-based cartridge production, process improvements, and lower service costs.
- On July 6, 2023, the FDA issued a warning letter concerning website promotion of continuous renal replacement therapy outside current Tablo indications and the regulatory status of TabloCart with Prefiltration.
- The company stated that it addressed the promotional issue and paused distribution of TabloCart with Prefiltration pending submission and FDA clearance of a 510(k) application. Timing and outcome of FDA review are uncertain, and potential consequences include additional remediation, recall, enforcement action, penalties, or business disruption.
- The FDA matter could adversely affect bookings, backlog, revenue, customer relationships, reputation, and growth prospects.
- Additional risks include continued healthcare labor shortages, customer budget pressure, longer sales cycles, supply-chain disruption, inflation, labor and component costs, rising interest rates, dependence on market acceptance of Tablo, and the need for additional financing.
- The company adopted the CECL credit-loss standard in the first quarter of 2023; adoption did not materially affect the financial statements.
- Unrealized losses on available-for-sale securities were attributed to interest-rate increases, with no credit losses recognized.
Important Facts for Investors to Verify
- Whether revenue growth and installed-base expansion continue to offset the company’s substantial operating losses and cash burn.
- Progress toward sustained gross-margin improvement and the effect of service revenue and lease expirations on margins.
- FDA review, clearance timing, and any further action related to TabloCart with Prefiltration and the warning letter.
- Compliance with SLR credit-facility covenants, including financial requirements beginning with the quarter ending December 31, 2023.
- Liquidity runway, future financing needs, potential equity dilution, and the cost of variable-rate debt.
- Customer adoption in acute-care and home settings, including the effects of staffing shortages and hospital budget constraints.
- Execution and cost benefits from Mexico-based and in-house manufacturing, as well as exposure to supply-chain and component-cost volatility.